Mineralys Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Samsara BioCapital and affiliated entities increased their beneficial ownership in Mineralys Therapeutics, Inc. to 8.2% following a recent public offering.
NASDAQ
RA Capital Management, L.P. and its affiliates increased their beneficial ownership in Mineralys Therapeutics, Inc. to 9.9% following a $30 million purchase in a September 2025 public offering.
NASDAQ
SCHEDULE 13D/A: Samsara BioCapital Increases Stake in Mineralys Therapeutics to 9.1% Following $8.1 Million Public Offering Purchase
Samsara BioCapital, L.P. and its affiliates have significantly increased their beneficial ownership in Mineralys Therapeutics, Inc. to 9.1% by acquiring 600,000 shares in a recent public offering.
NASDAQ
SCHEDULE 13D/A: RA Capital Increases Stake in Mineralys Therapeutics to 9.9% Following $17.5 Million Public Offering Investment
RA Capital Management and its affiliates have significantly increased their beneficial ownership in Mineralys Therapeutics, Inc. to 9.9% of outstanding common stock through a recent $17.5 million investment in a public offering.